1141PDGASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEPNET) REGISTRY: UPDATE FROM AN INTERNATIONAL COLLABORATION

ABSTRACT Aim: Epidemiologic data for GEPNET is lacking in many geographic areas. The aim of the GEPNET Registry is to study the prevalence, incidence, regional trends in diagnosis, and clinical management of GEPNET in the Asia-Pacific, Middle East, Turkey and South Africa. Methods: Patients (pts) with histopathological diagnosis of GEPNET within 5 years (yrs) of registry entry were included. Pro- and retrospective data were collected at 82 sites. Enrollment in the registry was from July 2009 to December 2012. Follow-up will be for 5 yrs. Results: As of December 1, 2013 (cut-off for this interim analysis), 1005 pts were enrolled, 933 were evaluable. At diagnosis, median age was 54 yrs [range: 12-87], gender ratio was balanced (49% male). The majority of pts (740/933, 77%) had symptoms at the time of diagnosis. Abdominal pain and weight loss were the most commonly reported symptoms. The most frequently reported primary site was the pancreas (42%) followed by the stomach (17%). The majority of pts had well-differentiated tumors (70%). Immunostaining results for Synaptophysin and Chromogranin A were reported for the majority of patients (77% and 82% respectively). Proliferative indices were less frequently reported; mitotic index: 17% and Ki-67: 50% pts. Use of computed tomography scanning was the main modality of disease evaluation (44% pts). Other imaging modalities including functional PET and octreotide scintigraphy were used in Conclusions: The GEPNET Registry continues to provide important information as it relates to the diagnosis and treatment of patients in the participating countries. This analysis has highlighted the need for clinical practice improvement to ensure better evaluation of patients. Disclosure: S. Yalcin: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials. S. Glasberg: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; H. Abali: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; F. Aykan: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; L. Bai: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; J. Kattan: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; H.Y. Lim: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; Y.S. Park: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; H. Raef: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; J. Ramos: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; K. Rau: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; S. Saglam: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; S. Serdengecti: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; A. Sevinc: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; Y. Shan: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; Y. Shyr: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials.; V. Sriuranpong: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; S.N. Turhal: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; K. Yeh: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials; T. Hwang: Member of Novartis Advisory Board; Institution participates in Novartis-sponsored clinical trials.